Bildkälla: Stockfoto

Cantargia: New Positive Readout in NSCLC - Redeye

Redeye comments on the new readout in non-small cell lung cancer presented at ASCO 2023. In particular, the complete response with nadunolimab as monotherapy is highly encouraging.

Redeye comments on the new readout in non-small cell lung cancer presented at ASCO 2023. In particular, the complete response with nadunolimab as monotherapy is highly encouraging.
Börsvärldens nyhetsbrev
ANNONSER